2010
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal Of The American Academy Of Dermatology 2010, 64: 352-404. PMID: 21145619, DOI: 10.1016/j.jaad.2010.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAlkylating AgentsAntibodies, MonoclonalAntineoplastic AgentsClinical Trials as TopicCombined Modality TherapyDrug Therapy, CombinationEvidence-Based MedicineHistone Deacetylase InhibitorsHumansImmunologic FactorsMethotrexateMycosis FungoidesQuality of LifeRetinoidsSezary SyndromeSkin NeoplasmsConceptsUnited States Cutaneous Lymphoma ConsortiumSézary syndromeTherapeutic optionsTreatment of SSPreventive services guidelinesCurrent treatment optionsEvidence-based medicineMechanism of actionAdjuvant treatmentMycosis fungoidesPoor prognosisCombination therapyTreatment optionsClinical trialsClinical carePromising treatmentSpecific efficacyStandardized reviewOverall efficacyStandardized criteriaTherapyService guidelinesAdverse effectsImmunopathogenesisTreatment
2003
Extracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease
Foss FM. Extracorporeal Photopheresis in the Treatment of Graft-vs-Host Disease. Journal Of Cutaneous Medicine And Surgery 2003, 7: 13-17. DOI: 10.1177/12034754030070s404.Peer-Reviewed Original ResearchAdrenal Cortex HormonesAdultAnimalsBone Marrow TransplantationChildClinical Trials as TopicDendritic CellsDisease Models, AnimalDogsFollow-Up StudiesGraft vs Host DiseaseHumansImmunosuppressive AgentsMicePentostatinPhotopheresisPilot ProjectsQuality of LifeRisk FactorsStem Cell TransplantationTime FactorsTissue DonorsTreatment OutcomeWhole-Body Irradiation
2002
Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®)
Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®). Clinical Lymphoma Myeloma & Leukemia 2002, 2: 222-228. PMID: 11970761, DOI: 10.3816/clm.2002.n.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsDiphtheria ToxinDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfusions, IntravenousInterleukin-2Lymphoma, T-Cell, CutaneousMaleMiddle AgedNeoplasm StagingPatient SatisfactionProbabilityPrognosisProspective StudiesQuality of LifeRecombinant Fusion ProteinsReference ValuesRisk AssessmentSkin NeoplasmsStatistics, NonparametricTreatment OutcomeConceptsCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaDenileukin diftitoxPruritus severityOverall QoLSkin appearanceCutaneous T-cell lymphoma patientsAdverse transfusion-related eventsCancer Therapy-General (FACT-G) questionnaireT-cell lymphoma patientsPhase III trialsVascular leak syndromeT-cell lymphomaTransfusion-related eventsSignificant myelosuppressionIII trialsSkin severityStudy endpointLymphoma patientsOutpatient basisIndividual subscale scoresFunctional assessmentPatientsDiftitoxTreatment cycles